Company Legal Name
Latest Valuation
Founded Year
Headquarter
Cambrian Biopharma Inc. develops innovative therapeutics targeting the biological mechanisms of aging and age-related diseases. Founded in 2019 and headquartered in New York, the biotechnology company focuses on addressing fundamental aging processes rather than individual age-related conditions. Cambrian's approach represents a paradigm shift in healthcare, moving beyond traditional disease treatment to target the underlying drivers of aging itself. The company operates in the emerging longevity biotechnology sector, which has gained significant investor and scientific interest as populations age globally. Cambrian continues advancing its pipeline of aging-targeted therapeutics through preclinical and clinical development programs.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
